Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 41.48
Day High 43.34
Open:42.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Acadia Pharmaceu Set to Possibly Pullback After Yesterday's Rally of 2.28%
- Comtex SmarTrend(R) - Mon Sep 23, 12:08PM CDT
Comtex SmarTrend(R) - CMTX
Mon Sep 23, 12:08PM CDT
Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $40.60 to a high of $43.16. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $42.58 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson's Disease and Movement Disorders
- BusinessWire - Mon Sep 23, 8:00AM CDT
BusinessWire - CMTX
Mon Sep 23, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive results from an 8-week, open-label, single-arm Phase 2 study evaluating an investigational use and safety of pimavanserin as a monotherapy or adjunct to selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) therapy for Parkinson's disease (PD) patients with depressive symptoms. These results were presented today during a poster session at the 2019 International Congress of Parkinson's Disease and Movement Disorders(R) (MDS) in Nice, France.
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- BusinessWire - Fri Sep 20, 3:05PM CDT
BusinessWire - CMTX
Fri Sep 20, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, which includes 937,500 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of $40.00 per share. The gross proceeds from the offering to ACADIA, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA, are approximately $287.5 million.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 23.77 +75.90% increase
on 09/06/19
Period Open:28.05
Price movement based on the high, low and last over the given period.
44.85 -6.78% decrease
on 09/16/19
+13.76 (+49.06%) increase
since 08/23/19
3-Month 21.56 +93.93% increase
on 07/23/19
Period Open:26.00
Price movement based on the high, low and last over the given period.
44.85 -6.78% decrease
on 09/16/19
+15.81 (+60.81%) increase
since 06/21/19
52-Week 14.01 +198.44% increase
on 12/24/18
Period Open:20.17
Price movement based on the high, low and last over the given period.
44.85 -6.78% decrease
on 09/16/19
+21.64 (+107.29%) increase
since 09/21/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).